Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 106Pancreatic Neoplasms 31Esophageal Neoplasms 17Esophageal Squamous Cell Carcinoma 11Biliary Tract Neoplasms 11Colorectal Neoplasms 10Cholangiocarcinoma 6Neoplasm Metastasis 5Nasopharyngeal Carcinoma 5Adenocarcinoma 5Recurrence 4Head and Neck Neoplasms 4Gastrointestinal Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3Advanced Pancreatic Cancer 3Advanced Gastric Cancer 3Stage IV Gastric Cancer With Metastasis 2Neoplasms 2NSCLC 2Locally Advanced Gastric Cancer 2Gastric Cancer Peritoneal Metastases 2Gastric Adenocarcinoma 2Gallbladder Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2mCRC 1Surgically-Created Resection Cavity 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

anlotinib 1S 1 (combination) 1Oxaliplatin 1Irinotecan 1Immune Checkpoint Inhibitors 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Overall Survival × S 1 (combination) × Clear all
NCT03726021 2023-03-29

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Qingdao Central Hospital

Phase 2 Completed
47 enrolled

Overall Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡